Open Label Study of Long Term Treatment of Pediatric Treatment of Atopic Dermatitis With Pimecrolimus Cream 1% Within a Usual Clinical Setting

Open Label Multicenter Study, 52 Weeks Duration, Using Pimecrolimus Cream 1% for the Long-term Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Patients Within a Usual Clinical Setting

An open-label, multicenter study, of long term management to evaluate effectiveness, tolerability and safety of pimecrolimus cream 1% in pediatric patients with mild to moderate atopic dermatitis in a daily practice

Inclusion Criteria:

• Age ≥ 3 months to 12 years old
• Clinical diagnosis of atopic dermatitis
• History of mild to moderate atopic dermatitis
• Investigator Global Assessment ≥ 1 (almost clear/clear of disease)
• Written informed consent

Exclusion Criteria:

• Investigator Global Assessment ≥ 4 (severe/very severe disease)
• Patients with active skin viral infections (i.e, herpes simplex, herpes zoster, varicella)
• Patients with atopic dermatitis, with active clinical infection on area of disease. All active infections must be treated prior to trial inclusion
• Patients in an Immunosuppressive state or with history of malignant disease
• Patients with clinical conditions other that Atopic Dermatitis that according to the investigator may interfere with the evaluation (i.e, Psoriasis, Netherton Syndrome)
• Other protocol-defined inclusion/exclusion criteria may apply